Distinct immune responses to proton and photon radiotherapy: implications for anti-PD-L1 combination therapy in colorectal cancer.

Fiche publication

Date publication

mars 2025

Journal

Journal of translational medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BOIDOT Romain , Dr MIRJOLET Céline , Pr NOEL Georges , Dr BURCKEL Hélène , Mme NICOL Anaïs , Dr LIMAGNE Emeric

Tous les auteurs :
Burckel H, Nicol A, Mura C, Rousseau M, Bou-Gharios J, Froidurot L, Richard C, Morgand V, Laurent PA, Limagne E, Boidot R, Noël G, Mirjolet C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40122794

Résumé

Ionizing radiation can influence the antitumor immune response, either activating or suppressing the immune system depending on the tumor type and radiotherapy modality. While photon radiation (RT) combined with immunotherapy (IT) is widely studied in clinical trials, proton radiation (PT) combined with IT has not been thoroughly investigated in clinical or preclinical studies despite its radiobiological advantages. This study aims to explore the immune effects of a hypofractionated PT scheme compared to RT and its efficacy with anti-PD-L1 immunotherapy.